Diethylcarbamazine Attenuates the Development of Carrageenan-Induced Lung Injury in Mice

• Published in: Mediators of Inflammation Vol. 2014; no. 1; pp. 20 - 31
• Main Authors: Peixoto, Christina Alves, Amaro da Silva Junior, Valdemiro, Silva, Amanda Karolina Soares e, Silva, Bruna Santos da, Oliveira dos Santos Gomes, Fabiana, Donato, Mariana Aragão Matos, Fragoso, Ingrid Tavares, Barbosa, Karla Patricia de Souza, Ribeiro, Edlene Lima, Rocha, Sura Wanessa Santos
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Limiteds 01-01-2014; Hindawi Publishing Corporation; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Administration, Oral; Animals; Anti-Inflammatory Agents - chemistry; Anti-inflammatory drugs; Carrageenan - adverse effects; Carrageenin; Cyclooxygenase 2 - metabolism; Diethylcarbamazine - chemistry; Gene Expression Regulation - drug effects; Inflammation; Interleukin-1beta - metabolism; Leukocytes - drug effects; Lipoxygenase Inhibitors - chemistry; Lung - metabolism; Lung Injury - chemically induced; Lung Injury - drug therapy; Male; Mice; Nitric oxide; Nitric Oxide Synthase Type II - metabolism; Physiological aspects; Pleurisy - chemically induced; Random Allocation; Tumor necrosis factor
• ISSN: 0962-9351; 1466-1861
• DOI: 10.1155/2014/105120

Diethylcarbamazine (DEC) is an antifilarial drug with potent anti-inflammatory properties as a result of its interference with the metabolism of arachidonic acid. The aim of the present study was to evaluate the anti-inflammatory activity of DEC in a mouse model of acute inflammation (carrageenan-induced pleurisy). The injection of carrageenan into the pleural cavity induced the accumulation of fluid containing a large number of polymorphonuclear cells (PMNs) as well as infiltration of PMNs in lung tissues and increased production of nitrite and tumor necrosis factor-α and increased expression of interleukin-1β, cyclooxygenase (COX-2), and inducible nitric oxide synthase. Carrageenan also induced the expression of nuclear factor-κB. The oral administration of DEC (50 mg/Kg) three days prior to the carrageenan challenge led to a significant reduction in all inflammation markers. The present findings demonstrate that DEC is a potential drug for the treatment of acute lung inflammation.